-transparent.png){kind=logo}
OBJECTIVE To identify, classify and quantify the frequency of negative clinical adverse drug reactions (ADR) resulting in hospital admission from the emergency department (ED). To determine ADR preventability, identify ADR-related admission factors, calculate related costs and recognise which drugs are the most often involved. METHODS Cross-sectional, prospective and observational study of patients that were admitted to hospital from the ED. We used the Dader method to detect ADR. We classified ADR in accordance with the Tercer Consenso de Granada (third Granada consensus), and calculated ADR preventability using the Schumock and Thornton scales (modified by Otero et al), and ADR severity according to Schneider. We considered the direct costs generated during the hospital stay for the economic study. We analysed the correlation between ADR and age, sex, kidney and liver failure, and drug use. We used multiple logistic regression analysis to identify risk factors. RESULTS 19.4% of admissions were the direct consequence of ADR, 65% of which were preventable. Antineoplastic therapy and immunosuppressants caused 38% of ADR. 20.4% of admissions had to be transferred to the intensive care unit (ICU) or caused permanent damage. We found statistical significance between ADR and patients undergoing hormonal therapy, 'high risk' drugs and those admitted to the endocrinology department. The ADR-associated cost was €237,377. CONCLUSIONS ADR-related admission is a problem with a high prevalence, and most cases are preventable.
C Pérez Menéndez-Conde, and
T Bermejo Vicedo, and
E Delgado Silveira, and
E Carretero Accame
August 1976,
Harefuah,
C Pérez Menéndez-Conde, and
T Bermejo Vicedo, and
E Delgado Silveira, and
E Carretero Accame
January 2002,
Revista da Associacao Medica Brasileira (1992),
C Pérez Menéndez-Conde, and
T Bermejo Vicedo, and
E Delgado Silveira, and
E Carretero Accame
January 1991,
Drug safety,
C Pérez Menéndez-Conde, and
T Bermejo Vicedo, and
E Delgado Silveira, and
E Carretero Accame
December 1994,
International journal of clinical pharmacology and therapeutics,
C Pérez Menéndez-Conde, and
T Bermejo Vicedo, and
E Delgado Silveira, and
E Carretero Accame
September 2003,
The Ceylon medical journal,
C Pérez Menéndez-Conde, and
T Bermejo Vicedo, and
E Delgado Silveira, and
E Carretero Accame
January 2012,
PloS one,
C Pérez Menéndez-Conde, and
T Bermejo Vicedo, and
E Delgado Silveira, and
E Carretero Accame
November 2000,
Age and ageing,
C Pérez Menéndez-Conde, and
T Bermejo Vicedo, and
E Delgado Silveira, and
E Carretero Accame
July 1988,
Pediatrics,
C Pérez Menéndez-Conde, and
T Bermejo Vicedo, and
E Delgado Silveira, and
E Carretero Accame
August 2004,
BMJ (Clinical research ed.),
C Pérez Menéndez-Conde, and
T Bermejo Vicedo, and
E Delgado Silveira, and
E Carretero Accame
January 2000,
Age and ageing,
